Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655125 | 0.89 | MGLL (0.34) | MGLLKMT2AATM | |
| SCHEMBL8358467 | 0.87 | GPR84 (0.46) | KMT2A | |
| SCHEMBL8359712 | 0.87 | GPR84 (0.46) | KMT2A | |
| SCHEMBL8361662 | 0.87 | GPR84 (0.46) | KMT2A | |
| SCHEMBL1480734 | 0.86 | ALDH1A1 (0.34) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL1820879 | 0.84 | HDAC1 (0.38) | MGLLKMT2AATM | |
| SCHEMBL10075274 | 0.83 | SMN1; SMN2 (0.35) | ALDH1A1HPGDMGLLKMT2AATM | |
| SCHEMBL19962869 | 0.81 | CA2 (0.40) | MGLLATM | |
| SCHEMBL9768638 | 0.79 | KMT2A (0.30) | KMT2A | |
| SCHEMBL19820110 | 0.79 | CA2 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271993-B2 | Treatment of bacterial infectious diseases | UNIVERSITY OF ZURICH (CH) | 2016-03-01 | — | — | US | disclosed |
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | ETH ZURICH (CH) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | APRT, BPGM, TLR5 | ALDH1A1 255/4885CYP1A2 859/4885HPGD 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.